

MIT Open Access Articles

Synapse development in health and disease

The MIT Faculty has made this article openly available. **Please share** how this access benefits you. Your story matters.

Citation: Melom, Jan Elizabeth, and J Troy Littleton. "Synapse Development in Health and Disease." *Current Opinion in Genetics & Development* 21, no. 3 (June 2011): 256–261.

As Published: <http://dx.doi.org/10.1016/j.gde.2011.01.002>

Publisher: Elsevier

Persistent URL: <http://hdl.handle.net/1721.1/105487>

Version: Author's final manuscript: final author's manuscript post peer review, without publisher's formatting or copy editing

Terms of use: Creative Commons Attribution-NonCommercial-NoDerivs License



Synapse development in health and disease

Abbreviated title: Disorders of Synapse Development

Authors:

Jan Elizabeth Melom

Department of Biology

The Picower Institute for Learning and Memory

Massachusetts Institute of Technology

43 Vassar St. 46-3251

Cambridge, MA 02139

jmelom@mit.edu

J. Troy Littleton (corresponding author)

Department of Biology

Department of Brain and Cognitive Sciences

The Picower Institute for Learning and Memory

Massachusetts Institute of Technology

43 Vassar St. 46-3251

Cambridge, MA 02139

troy@mit.edu

Summary

Recent insights into the genetic basis of neurological disease have led to the hypothesis that molecular pathways involved in synaptic growth, development, and stability are perturbed in a variety of mental disorders. Formation of a functional synapse is a complex process requiring stabilization of initial synaptic contacts by adhesive protein interactions, organization of pre- and post-synaptic specializations by scaffolding proteins, regulation of growth by intercellular signaling pathways, reorganization of the actin cytoskeleton, and proper endosomal trafficking of synaptic growth signaling complexes. Many neuropsychiatric disorders, including autism, schizophrenia, and intellectual disability, have been linked to inherited mutations which perturb these processes. Our understanding of the basic biology of synaptogenesis is therefore critical to unraveling the pathogenesis of neuropsychiatric disorders.

Introduction

The formation of a functional, mature neuronal synapse requires a host of molecular players to mediate coordinated pre- and post-synaptic growth. In recent years, clinically diverse disorders such as autism spectrum disorders (ASDs), schizophrenia, epilepsy, and intellectual disability (ID) have been linked to dysfunction of a number of proteins implicated in synaptic development [1,2]. For example, deletions of neurexin-1 α , a synaptic cell adhesion protein, were initially identified by large-scale genetic screens in patients with autism and schizophrenia, and subsequently found in patients with severe ID and epilepsy [3]. Mutations in genes encoding the SHANK postsynaptic scaffolding protein family were first identified in a patient with ID, and later associated with autism

and schizophrenia [4,5]. As the number of genes contributing to neuropsychiatric disorders has grown, it has become increasingly clear that pathways contributing to synaptic development and activity-dependent growth are important in their etiology.

Here, we examine genes implicated in synaptogenesis which have been associated with neurological disease. In particular, we highlight the role of these genes in synaptic cell adhesion, organization of pre- and post-synaptic specializations, growth signaling pathways, and endosomal function. Insights into the function of these genes at the *Drosophila* neuromuscular junction (NMJ) are emphasized, as this model glutamatergic synapse is well studied within the context of activity-dependent synaptic development.

Specification and stabilization of the synapse is mediated by cell adhesion proteins

One of the earliest steps in synaptogenesis is the induction and adhesion of precisely opposed pre- and post-synaptic domains. Multiple transsynaptic cell adhesion complexes operate in parallel to ensure proper synaptic alignment (Figure 1). Mutation of synaptic adhesion proteins has been linked to various neuropsychiatric disorders, indicating that abnormal formation or maintenance of synaptic contacts may be impaired in several neurological diseases [6]. Members of the cadherin and immunoglobulin protein superfamilies play an important role in mediating synaptic adhesion. Synaptic cell adhesion molecule 1 (SynCAM1) is an immunoglobulin domain containing protein found on axonal growth cones, and is one of the first transsynaptic adhesion molecules to assemble at developing synapses [7]. Homophilic binding of SynCAM1 across the synaptic cleft promotes synapse formation in cultured hippocampal neurons [7]. Recently, missense mutations in SynCAM1 have been identified in patients with ASDs, and a

SynCAM1 knock-out mouse was found to have impaired social behaviors [8,9]. Mutations in a *Drosophila* SynCAM-like protein, FasII, disrupt synaptic growth at the NMJ due to synaptic destabilization [10]. Several members of the cadherin protein family, including protocadherins, also mediate transsynaptic adhesion and have been linked to ASDs in genome-wide association studies [11,12]. The role of cadherins and protocadherins in synaptogenesis is poorly understood, although they likely participate in synapse formation and refinement.

One well studied transsynaptic adhesion complex is neurexin-neuroigin. Mutations in neurexins and neuroiginins have been identified in several families with heritable neurological disorders, including ASDs, schizophrenia, and ID [13]. The binding of a presynaptic neurexin to a postsynaptic neuroigin is required for synapse function, but whether neurexin-neuroigin binding affects synapse formation is unclear [13]. In *Drosophila*, mutations in the homolog of neurexin, *dnrx*, cause reduced synaptic growth and defective presynaptic active zone formation [14]. Likewise, mutations in neuroigin, *dnlgl*, decrease synaptic growth due to deficits in bouton addition and postsynaptic differentiation [15]. In mammals, a synaptogenic role for neurexins is suggested by the observation that neurexins bind the postsynaptic glutamate receptor $\delta 2$ via an adaptor protein, which is essential for excitatory synaptogenesis in the cerebellum [16].

Another family of postsynaptic cell adhesion proteins, the leucine-rich repeat transmembrane proteins (LRRTMs), were identified in a screen for synaptogenic proteins and subsequently found to bind neurexins [17-19]. Similar to neurexins and neuroiginins, mutations in LRRTMs have been associated with both autism and schizophrenia, and are

thought to promote synapse formation [20,21]. The netrin-G ligand (NGL) proteins form a subfamily of LRRTM synaptic adhesion molecules implicated in the etiology of schizophrenia and bipolar disorder [22,23]. NGLs promote excitatory synaptogenesis by binding to presynaptic netrin G and LAR receptors, as well as postsynaptic proteins [23]. The combinatorial action of neuexins, neuroligins, LRRTMs, and NGLs is not well understood, and these complexes may act redundantly at the synapse.

Several other cell adhesion proteins whose synaptic role is unclear have also been associated with neurological disease. Contactin-associated protein-2 (CNTNAP2) is a single-pass transmembrane protein distantly related to neuexins, and is associated with ASDs, schizophrenia, ID, and epilepsy by genome-wide linkage analysis [24]. A synaptic role for CNTNAP2 was recently demonstrated in *Drosophila*, in which neuronal knockdown of CNTNAP2 (NrXIV) resulted in aberrant synaptic morphology and misregulation of a critical active zone component [3]. Another recently recognized synaptic cell adhesion molecule is amyloid precursor protein (APP), a type I membrane protein involved in Alzheimer's disease pathogenesis. APP was found to promote synaptogenesis in culture and is required both pre- and post-synaptically to regulate mammalian NMJ structure and function, presumably by forming a transsynaptic adhesion complex [25]. Similarly, regulation of the *Drosophila* APP homolog critically controls synaptic growth at the NMJ [26]. The involvement of various synaptic cell adhesion proteins in neuropsychiatric diseases indicates that abnormal synapse formation or specification may be a common risk factor for mental disorders.

Organization of pre- and post-synaptic domains by scaffolding proteins

Formation of a functional synapse requires assembly of synaptic proteins into domains specialized for neurotransmitter release and reception. Scaffolding proteins are critical mediators of this process on both sides of the synapse. Scaffolds are composed of multiple protein-protein interaction domains, and form a physical link between adhesion proteins, ion channels, neurotransmitter receptors, intracellular signaling cascades, and the actin cytoskeleton.

One of the strongest links between synaptic organization and neurological disease is the SHANK family of scaffolding proteins. SHANK proteins localize to the excitatory postsynaptic density and contain multiple protein-protein interaction domains. Mutations in SHANK2 and SHANK3 have been identified in patients with autism, mental retardation, and schizophrenia [4,5]. In conjunction with HOMER, SHANKs form a mesh-like matrix at the postsynaptic density which regulates the morphology of dendritic spines and recruits postsynaptic density proteins [27]. The connection between SHANK scaffolds and mental dysfunction was recently strengthened by the finding that FMRP, the RNA binding protein mutated in Fragile X syndrome, inhibits the translation of SHANK1 [28]. Fragile X syndrome is the most common inherited form of mental retardation and is associated with abnormal dendritic morphology. Deregulated synthesis of SHANK scaffolds may contribute to this abnormal morphology.

The membrane-associated guanylate kinase (MAGUK) scaffolding protein family has multiple members that are present pre- and post-synaptically. One MAGUK family member, CASK, is a causative gene in X-linked mental retardation [29]. CASK is an essential vertebrate protein involved in assembly and functional maturation of the synapse [30]. Interestingly, CASK directly interacts with neurexin-1, which it

phosphorylates in a developmentally regulated manner [29], although the functional significance of neurexin phosphorylation is unclear. CASK also interacts with the adhesion protein SynCAM1, which recruits CASK from cytosol to the membrane [31]. The strong association of mutations in presynaptic CASK and postsynaptic SHANKs with neurological disease highlights an important role for synaptic scaffolding proteins.

Activity-dependent synaptic development depends on intercellular signaling pathways

Once a synapse has formed, neuronal activity plays an essential role in shaping and maintaining synaptic connections [32]. Anterograde and retrograde secreted signaling molecules, including the Wnts and BMPs, regulate synaptic growth (Figure 1) and may also contribute to the development of neurological disease. The Wnt family of signaling molecules participates in a broad range of processes, from neurogenesis to synaptic plasticity. Several Wnt pathway components have been implicated in the pathogenesis of schizophrenia and Alzheimer's, raising the question of how this pathway functions at the synapse [33,34]. At the *Drosophila* NMJ, the Wnt pathway signals bidirectionally to mediate synaptic growth in response to patterned neuronal stimulation [35]. Presynaptically, Wnt regulates cytoskeletal dynamics through inhibition of glycogen synthase kinase 3 β (GSK-3 β), a cytoplasmic pathway component which interacts with the microtubule and actin cytoskeletons. Single nucleotide polymorphisms in GSK-3 β are associated with schizophrenia, and GSK-3 β was recently found to interact with DISC1, a major schizophrenia susceptibility gene [33,36]. Postsynaptically, Wnt signaling causes translocation of the cleaved receptor Frizzled into the nucleus, which promotes growth of

the postsynaptic membrane [35,37]. Polymorphisms in Wnt signaling components have been linked to neurodegenerative diseases such as Alzheimer's, though whether this late-onset disease is related to Wnt's synaptogenic function is unclear [38].

A second synaptic growth signaling pathway is the bone morphogenetic protein (BMP) pathway, dysregulation of which is associated with multiple neurodegenerative diseases [39]. Retrograde BMP signaling at the *Drosophila* NMJ is initiated by release of the BMP ligand Gbb by the muscle, which triggers a signaling cascade in the presynaptic neuron [40]. BMP signaling activates a transcription factor which targets multiple genes, including a recently described Rac GTPase activator [40]. Rac GTPases regulate the actin cytoskeleton and are important for growth of dendritic spines, which mechanistically links BMP signaling to structural synaptic plasticity [41]. Recently, synaptic Rac1 GTPase activity was shown to be regulated by FMRP and DISC1, raising the possibility that both Fragile X and schizophrenia may have impaired BMP mediated activity-dependent synaptic growth [42,43].

Synaptic growth signaling requires proper endosomal trafficking

Regulation of endosomal traffic is a critical component of synaptic growth and development. Growth signals released during activity, such as the Wnts and BMPs described above, bind to synaptic transmembrane receptors and are internalized as receptor-ligand signaling complexes. These signaling complexes are transported within the endosomal system, in which receptors signal from an early endosome population before signal inactivation in the recycling endosome or lysosome (Figure 2). Many of the synaptic growth mutants identified in *Drosophila* alter endocytic trafficking, with

mutants that disrupt formation of signaling endosomes causing reduced synaptic growth, and mutants altering traffic to the recycling endosome or lysosome causing synaptic overgrowth due to enhanced signaling [44,45]. Retrograde transport of signaling endosomes containing neurotrophins is also important for neuronal survival and may be disrupted in neurodegenerative diseases such as Alzheimer's and Down's syndrome [46].

The hereditary spastic paraplegias (HSPs) are a group of neurological disorders caused by mutations in several genes which regulate the endosomal trafficking of BMP receptors [39,47]. Mutation of the early endosomal HSP gene NIPA1 results in less efficient sorting of the type II BMP receptor to the lysosome, suggesting that HSP etiology may involve upregulation of BMP signaling due to altered endocytic trafficking [47]. Disruption of endosomal function is also implicated in neurodevelopmental disorders, including autism and attention-deficient/hyperactivity disorder, for which recent genome-wide association and copy number variation studies have implicated the Na⁺/H⁺ exchangers 6 and 9 (NHE6, 9) [48,49]. NHE6 and 9 are thought to fine-tune the pH of early endosomes, disruption of which may alter ligand-receptor dissociation and lead to abnormal synaptic growth signaling [50]. Endosomal regulation of signaling pathways involved in synaptic growth and development appears critical for activity-dependent circuit refinement.

Conclusion

Abnormal synaptic development is thought to underlie multiple neurodevelopmental disorders which present with clinically distinct phenotypes. Altered synaptic structure or function may also lead to changes in neuronal connectivity which

predisposes an individual to neurodegenerative disease. We have highlighted several genes implicated in neuropsychiatric disease which have defined roles in synaptic development. Mutations in different genes or gene combinations may lead to a similar disease phenotype; thus understanding common molecular pathways in which these genes function is important for unraveling disease pathogenesis. Recent advances in genome sequencing and large scale genetic screening has identified numerous susceptibility loci which converge on pathways involved in synaptogenesis. Our understanding of the basic biology of synaptic growth and development is critical to furthering our understanding of synaptic dysfunction in brain disorders.

Figures Legends

Fig. 1. Proteins implicated in neuropsychiatric disorders that participate in synaptic growth and development. Formation of a functional synapse requires transsynaptic interaction of cell adhesive proteins, organization of synaptic domains by scaffolding proteins, intercellular growth signaling pathways, actin cytoskeletal remodeling, and endosomal trafficking of receptor-ligand signaling complexes. Many of the proteins associated with brain disorders have been implicated in these processes.

Fig. 2. Endosomal regulation of synaptic growth signaling pathways. Growth signals released during neuronal activity, including Wnts and BMPs, bind to presynaptic receptors and are internalized as receptor-ligand signaling complexes. These complexes

signal from early endosomes, and are recycled to the plasma membrane through the recycling endosome or degraded in the lysosome.

References

1. Mitchell KJ: **The genetics of neurodevelopmental disease.** *Curr Opin Neurobiol* 2010.
 2. Guilmatre A, Dubourg C, Mosca AL, Legallic S, Goldenberg A, Drouin-Garraud V, Layet V, Rosier A, Briault S, Bonnet-Brilhaut F, et al.: **Recurrent rearrangements in synaptic and neurodevelopmental genes and shared biologic pathways in schizophrenia, autism, and mental retardation.** *Arch Gen Psychiatry* 2009, **66**:947-956.
 3. Zweier C, de Jong EK, Zweier M, Orrico A, Ousager LB, Collins AL, Bijlsma EK, Oortveld MA, Ekici AB, Reis A, et al.: **CNTNAP2 and NRXN1 are mutated in autosomal-recessive Pitt-Hopkins-like mental retardation and determine the level of a common synaptic protein in Drosophila.** *Am J Hum Genet* 2009, **85**:655-666.
 4. Gauthier J, Champagne N, Lafreniere RG, Xiong L, Spiegelman D, Brustein E, Lapointe M, Peng H, Cote M, Noreau A, et al.: **De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia.** *Proc Natl Acad Sci U S A* 2010, **107**:7863-7868.
 5. Berkel S, Marshall CR, Weiss B, Howe J, Roeth R, Moog U, Endris V, Roberts W, Szatmari P, Pinto D, et al.: **Mutations in the SHANK2 synaptic scaffolding gene in autism spectrum disorder and mental retardation.** *Nat Genet* 2010, **42**:489-491.
 6. Giagtzoglou N, Ly CV, Bellen HJ: **Cell adhesion, the backbone of the synapse: "vertebrate" and "invertebrate" perspectives.** *Cold Spring Harb Perspect Biol* 2009, **1**:a003079.
 - 7. Stagi M, Fogel AI, Biederer T: **SynCAM 1 participates in axo-dendritic contact assembly and shapes neuronal growth cones.** *Proc Natl Acad Sci U S A* 2010, **107**:7568-7573.
- The authors report that SynCAM1 is required on developing neuronal growth cones to regulate neurite morphology. This study is the first to identify a role for SynCAM1 in events prior to synapse formation.
8. Zhiling Y, Fujita E, Tanabe Y, Yamagata T, Momoi T, Momoi MY: **Mutations in the gene encoding CADM1 are associated with autism spectrum disorder.** *Biochem Biophys Res Commun* 2008, **377**:926-929.

9. Takayanagi Y, Fujita E, Yu Z, Yamagata T, Momoi MY, Momoi T, Onaka T: **Impairment of social and emotional behaviors in *Cadm1*-knockout mice.** *Biochem Biophys Res Commun* 2010, **396**:703-708.

10. Schuster CM, Davis GW, Fetter RD, Goodman CS: **Genetic dissection of structural and functional components of synaptic plasticity. I. Fasciclin II controls synaptic stabilization and growth.** *Neuron* 1996, **17**:641-654.

11. Arikath J, Reichardt LF: **Cadherins and catenins at synapses: roles in synaptogenesis and synaptic plasticity.** *Trends Neurosci* 2008, **31**:487-494.

12. Wang K, Zhang H, Ma D, Bucan M, Glessner JT, Abrahams BS, Salyakina D, Imielinski M, Bradfield JP, Sleiman PM, et al.: **Common genetic variants on *5p14.1* associate with autism spectrum disorders.** *Nature* 2009, **459**:528-533.

13. Sudhof TC: **Neuroligins and neuroligins link synaptic function to cognitive disease.** *Nature* 2008, **455**:903-911.

14. Li J, Ashley J, Budnik V, Bhat MA: **Crucial role of *Drosophila* neuroligin in proper active zone apposition to postsynaptic densities, synaptic growth, and synaptic transmission.** *Neuron* 2007, **55**:741-755.

•15. Banovic D, Khorramshahi O, Oswald D, Wichmann C, Riedt T, Fouquet W, Tian R, Sigrist SJ, Aberle H: ***Drosophila* neuroligin 1 promotes growth and postsynaptic differentiation at glutamatergic neuromuscular junctions.** *Neuron* 2010, **66**:724-738.

This group identified *Drosophila* neuroligin, *dnlgl*, in an unbiased genetic screen for mutations that disrupt synaptic growth. Dnlgl promotes postsynaptic differentiation and addition of new synaptic boutons at the NMJ, but is not required for initial synaptic formation.

••16. Uemura T, Lee SJ, Yasumura M, Takeuchi T, Yoshida T, Ra M, Taguchi R, Sakimura K, Mishina M: **Trans-synaptic interaction of *GluRdelta2* and Neuroligin through *Cbln1* mediates synapse formation in the cerebellum.** *Cell* 2010, **141**:1068-1079.

This study indicates that a transsynaptic interaction between the postsynaptic glutamate receptor 2 δ subunit, *Cbln1*, and the presynaptic transmembrane protein Neuroligin mediates synaptogenesis *in vivo*.

17. Linhoff MW, Lauren J, Cassidy RM, Dobie FA, Takahashi H, Nygaard HB, Airaksinen MS, Strittmatter SM, Craig AM: **An unbiased expression screen for synaptogenic proteins identifies the LRRTM protein family as synaptic organizers.** *Neuron* 2009, **61**:734-749.

••18. Ko J, Fuccillo MV, Malenka RC, Sudhof TC: **LRRTM2 functions as a neuroligin ligand in promoting excitatory synapse formation.** *Neuron* 2009, **64**:791-798.

This study, along with [19], identifies the LRRTM protein family as novel Neurexin ligands which promote excitatory synapse formation. Neurexin binding to LRRTM was found to depend on alternative splicing of Neurexin, which may contribute to specificity of synapse formation.

••19. de Wit J, Sylwestrak E, O'Sullivan ML, Otto S, Tiglio K, Savas JN, Yates JR, 3rd, Comoletti D, Taylor P, Ghosh A: **LRRTM2 interacts with Neurexin1 and regulates excitatory synapse formation.** *Neuron* 2009, **64**:799-806.

This study also describes LRRTM-Neurexin interaction in excitatory synaptogenesis independent of [18]. This group found that LRRTM alters synaptic function by regulating surface expression of AMPA receptors.

20. Francks C, Maegawa S, Lauren J, Abrahams BS, Velayos-Baeza A, Medland SE, Colella S, Groszer M, McAuley EZ, Caffrey TM, et al.: **LRRTM1 on chromosome 2p12 is a maternally suppressed gene that is associated paternally with handedness and schizophrenia.** *Mol Psychiatry* 2007, **12**:1129-1139, 1057.

21. Sousa I, Clark TG, Holt R, Pagnamenta AT, Mulder EJ, Minderaa RB, Bailey AJ, Battaglia A, Klauck SM, Poustka F, et al.: **Polymorphisms in leucine-rich repeat genes are associated with autism spectrum disorder susceptibility in populations of European ancestry.** *Mol Autism* 2010, **1**:7.

22. Woo J, Kwon SK, Kim E: **The NGL family of leucine-rich repeat-containing synaptic adhesion molecules.** *Mol Cell Neurosci* 2009, **42**:1-10.

•23. Woo J, Kwon SK, Choi S, Kim S, Lee JR, Dunah AW, Sheng M, Kim E: **Trans-synaptic adhesion between NGL-3 and LAR regulates the formation of excitatory synapses.** *Nat Neurosci* 2009, **12**:428-437.

This study identifies a transsynaptic interaction between presynaptic LAR and postsynaptic NLG-3 which appears to function in excitatory synaptogenesis.

24. Burbach JP, van der Zwaag B: **Contact in the genetics of autism and schizophrenia.** *Trends Neurosci* 2009, **32**:69-72.

•25. Wang Z, Wang B, Yang L, Guo Q, Aithmitti N, Songyang Z, Zheng H: **Presynaptic and postsynaptic interaction of the amyloid precursor protein promotes peripheral and central synaptogenesis.** *J Neurosci* 2009, **29**:10788-10801.

By studying mice lacking APP either in neurons or muscles, the authors found that APP is required in both compartments to regulate structure and function of the developing neuromuscular junction. The authors also found that the intracellular domain of SynCAM1 can functionally replace the APP intracellular domain in a synaptogenesis culture assay, indicating that common intracellular interactions may occur downstream of both synaptic cell adhesion molecules.

26. Torroja L, Packard M, Gorczyca M, White K, Budnik V: **The Drosophila beta-amyloid precursor protein homolog promotes synapse differentiation at the neuromuscular junction.** *J Neurosci* 1999, **19**:7793-7803.

•27. Hayashi MK, Tang C, Verpelli C, Narayanan R, Stearns MH, Xu RM, Li H, Sala C, Hayashi Y: **The postsynaptic density proteins Homer and Shank form a polymeric network structure.** *Cell* 2009, **137**:159-171.

The authors of this study found that the postsynaptic proteins Homer and Shank interact to form a mesh-like network which may serve as a structural framework for the postsynaptic density. Disruption of the ability of Homer to multimerize reduces the postsynaptic localization of PSD-95 and affects spine structure and function.

28. Schutt J, Falley K, Richter D, Kreienkamp HJ, Kindler S: **Fragile X mental retardation protein regulates the levels of scaffold proteins and glutamate receptors in postsynaptic densities.** *J Biol Chem* 2009, **284**:25479-25487.

29. Mukherjee K, Sharma M, Urlaub H, Bourenkov GP, Jahn R, Sudhof TC, Wahl MC: **CASK Functions as a Mg²⁺-independent neurexin kinase.** *Cell* 2008, **133**:328-339.

30. Hsueh YP: **Calcium/calmodulin-dependent serine protein kinase and mental retardation.** *Ann Neurol* 2009, **66**:438-443.

31. Biederer T, Sara Y, Mozhayeva M, Atasoy D, Liu X, Kavalali ET, Sudhof TC: **SynCAM, a synaptic adhesion molecule that drives synapse assembly.** *Science* 2002, **297**:1525-1531.

32. Saneyoshi T, Fortin DA, Soderling TR: **Regulation of spine and synapse formation by activity-dependent intracellular signaling pathways.** *Curr Opin Neurobiol* 2010, **20**:108-115.

33. Freyberg Z, Ferrando SJ, Javitch JA: **Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action.** *Am J Psychiatry* 2010, **167**:388-396.

34. De Ferrari GV, Moon RT: **The ups and downs of Wnt signaling in prevalent neurological disorders.** *Oncogene* 2006, **25**:7545-7553.

35. Ataman B, Ashley J, Gorczyca M, Ramachandran P, Fouquet W, Sigrist SJ, Budnik V: **Rapid activity-dependent modifications in synaptic structure and function require bidirectional Wnt signaling.** *Neuron* 2008, **57**:705-718.

••36. Mao Y, Ge X, Frank CL, Madison JM, Koehler AN, Doud MK, Tassa C, Berry EM, Soda T, Singh KK, et al.: **Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling.** *Cell* 2009, **136**:1017-1031.

The authors demonstrate a novel role for DISC1 in neural progenitor cell proliferation that depends on DISC1 regulation of GSK3 β , a downstream mediator of the Wnt signaling pathway. These findings suggest that loss of DISC1 may affect neuronal development, which could lead to enhanced susceptibility to psychiatric disorders.

37. Mosca TJ, Schwarz TL: **The nuclear import of Frizzled2-C by Importins-beta11 and alpha2 promotes postsynaptic development.** *Nat Neurosci* 2010, **13**:935-943.

38. Inestrosa NC, Arenas E: **Emerging roles of Wnts in the adult nervous system.** *Nat Rev Neurosci* 2010, **11**:77-86.

39. Bayat V, Jaiswal M, Bellen HJ: **The BMP signaling pathway at the Drosophila neuromuscular junction and its links to neurodegenerative diseases.** *Curr Opin Neurobiol* 2010.

••40. Ball RW, Warren-Paquin M, Tsurudome K, Liao EH, Elazzouzi F, Cavanagh C, An BS, Wang TT, White JH, Haghighi AP: **Retrograde BMP signaling controls synaptic growth at the NMJ by regulating trio expression in motor neurons.** *Neuron* 2010, **66**:536-549.

This study shows that retrograde BMP signaling at the NMJ regulates synaptic growth through transcriptional activation of the Rac GEF Trio, a cytoskeletal regulator. This finding is an important first step in elucidating the mechanism by which the BMP pathway controls synaptic remodeling.

41. Corbetta S, Gualdoni S, Ciceri G, Monari M, Zuccaro E, Tybulewicz VL, de Curtis I: **Essential role of Rac1 and Rac3 GTPases in neuronal development.** *FASEB J* 2009, **23**:1347-1357.

42. Hayashi-Takagi A, Takaki M, Graziane N, Seshadri S, Murdoch H, Dunlop AJ, Makino Y, Seshadri AJ, Ishizuka K, Srivastava DP, et al.: **Disrupted-in-Schizophrenia 1 (DISC1) regulates spines of the glutamate synapse via Rac1.** *Nat Neurosci* 2010, **13**:327-332.

43. Chen LY, Rex CS, Babayan AH, Kramar EA, Lynch G, Gall CM, Lauterborn JC: **Physiological activation of synaptic Rac>PAK (p-21 activated kinase) signaling is defective in a mouse model of fragile X syndrome.** *J Neurosci* 2010, **30**:10977-10984.

44. Rodal AA, Motola-Barnes RN, Littleton JT: **Nervous wreck and Cdc42 cooperate to regulate endocytic actin assembly during synaptic growth.** *J Neurosci* 2008, **28**:8316-8325.

45. O'Connor-Giles KM, Ho LL, Ganetzky B: **Nervous wreck interacts with thickveins and the endocytic machinery to attenuate retrograde BMP signaling during synaptic growth.** *Neuron* 2008, **58**:507-518.

46. Wu C, Cui B, He L, Chen L, Mobley WC: **The coming of age of axonal neurotrophin signaling endosomes.** *J Proteomics* 2009, **72**:46-55.

47. Tsang HT, Edwards TL, Wang X, Connell JW, Davies RJ, Durrington HJ, O'Kane CJ, Luzio JP, Reid E: **The hereditary spastic paraplegia proteins NIPA1, spastin and spartin are inhibitors of mammalian BMP signalling.** *Hum Mol Genet* 2009, **18**:3805-3821.
48. Morrow EM, Yoo SY, Flavell SW, Kim TK, Lin Y, Hill RS, Mukaddes NM, Balkhy S, Gascon G, Hashmi A, et al.: **Identifying autism loci and genes by tracing recent shared ancestry.** *Science* 2008, **321**:218-223.
49. Mick E, Todorov A, Smalley S, Hu X, Loo S, Todd RD, Biederman J, Byrne D, Dechairo B, Guiney A, et al.: **Family-based genome-wide association scan of attention-deficit/hyperactivity disorder.** *J Am Acad Child Adolesc Psychiatry* 2010, **49**:898-905 e893.
50. Roxrud I, Raiborg C, Gilfillan GD, Stromme P, Stenmark H: **Dual degradation mechanisms ensure disposal of NHE6 mutant protein associated with neurological disease.** *Exp Cell Res* 2009, **315**:3014-3027.



